Manuela Lima Selected Research

Machado-Joseph Disease (Spinocerebellar Ataxia Type 3)

1/2022	Genetic Variation in ATXN3 (Ataxin-3) 3'UTR: Insights into the Downstream Regulatory Elements of the Causative Gene of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3.
1/2022	Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.
1/2022	Novel Machado-Joseph disease-modifying genes and pathways identified by whole-exome sequencing.
11/2021	Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood.
1/2020	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice.
11/2019	Selection of Reference Genes for Normalization of Gene Expression Data in Blood of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (MJD/SCA3) Subjects.
1/2019	Accumulation of Mitochondrial DNA Common Deletion Since The Preataxic Stage of Machado-Joseph Disease.
1/2018	Towards the Identification of Molecular Biomarkers of Spinocerebellar Ataxia Type 3 (SCA3)/Machado-Joseph Disease (MJD).
12/2017	Promoter Variant Alters Expression of the Autophagic BECN1 Gene: Implications for Clinical Manifestations of Machado-Joseph Disease.
3/2017	Promoter Variation and Expression Levels of Inflammatory Genes IL1A, IL1B, IL6 and TNF in Blood of Spinocerebellar Ataxia Type 3 (SCA3) Patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuela Lima Research Topics

Disease

16	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 01/2022 - 05/2010
3	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 06/2015
3	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 12/2016 - 01/2016
2	Neoplasms (Cancer) 11/2011 - 07/2009
1	Disease Progression 01/2019
1	Carcinogenesis 10/2018
1	Lung Neoplasms (Lung Cancer) 10/2018
1	Ankylosing Spondylitis 01/2018
1	Inflammation (Inflammations) 03/2017
1	Huntington Disease (Huntington's Disease) 06/2016
1	Nervous System Heredodegenerative Disorders 06/2016
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 12/2014
1	Chondrocalcinosis (Pseudogout) 01/2014
1	Hypokinesia (Bradykinesia) 10/2011
1	Parkinson Disease (Parkinson's Disease) 10/2011
1	Tremor (Tremors) 10/2011
1	Myocardial Infarction 05/2011
1	Dyslipidemias (Dyslipidemia) 05/2011
1	Atherosclerosis 05/2011
1	Urinary Bladder Neoplasms (Bladder Cancer) 07/2009

Drug/Important Bio-Agent (IBA)

7	polyglutamineIBA 01/2022 - 06/2015
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2015
5	Mitochondrial DNA (mtDNA)IBA 01/2019 - 10/2011
3	Ataxin-3IBA 11/2021 - 03/2013
3	Apolipoproteins E (ApoE)IBA 12/2011 - 05/2011
1	3' Untranslated Regions (3' UTR)IBA 01/2022
1	Biological ProductsIBA 10/2018
1	RadonIBA 10/2018
1	AntigensIBA 01/2018
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2018
1	Mutant Proteins (Protein, Mutant)IBA 12/2017
1	Interleukin-6 (Interleukin 6)IBA 03/2017
1	CytokinesIBA 03/2017
1	Proteins (Proteins, Gene)FDA Link 06/2015
1	CholesterolIBA 12/2014
1	Infliximab (Remicade)FDA Link 01/2014
1	ApolipoproteinsIBA 12/2011
1	Gln Transfer RNAIBA 10/2011
1	LipidsIBA 05/2011
1	Messenger RNA (mRNA)IBA 05/2010
1	DNA (Deoxyribonucleic Acid)IBA 05/2010
1	CadmiumIBA 07/2009
1	ChromiumIBA 07/2009
1	MetallothioneinIBA 07/2009
1	ArsenicIBA 07/2009
1	NickelIBA 07/2009